Company
Headquarters: Macquarie Park, NSW, Australia
CEO: Dr. Ronald Peter Weinberger AIMM, BSc (Hons), Ph.D.
A$169.6 Million
AUD as of July 1, 2024
US$112.9 Million
| Company | Market Cap (USD) |
|---|---|
| Abbott | $216.15 B |
| Boston Scientific Corporation | $140.40 B |
| Stryker | $133.15 B |
| Medtronic | $123.20 B |
| Edwards Lifesciences Corporation | $50.10 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $968.50 B |
| Johnson & Johnson | $499.57 B |
| AbbVie | $405.28 B |
| Roche | $332.12 B |
| UnitedHealth Group | $304.72 B |
EMvision Medical Devices Limited, a medical device company, engages in the research, development, and commercialization of imaging and diagnostic technology products. It develops a portable brain scanner for point of care, stroke diagnosis, and monitoring. The company was incorporated in 2017 and is based in Macquarie Park, Australia.
EMvision Medical Devices Limited has the following listings and related stock indices.
Stock: ASX: EMV